Our Board is driven by sound corporate governance.

Garry A. Nicholson was appointed to our Board of Directors in May 2015. Mr. Nicholson has 20 years of experience in oncology drug development and commercialization. He also serves as a board director of SQZ Biotechnologies. Previously, he served as President, Pfizer Oncology, from May 2008 until March 2015. As the first leader of Pfizer's global, dedicated oncology business, Mr. Nicholson had direct responsibility for business strategy and operations, including the oncology sales and marketing organizations globally, clinical development for both early and late stage pipeline candidates, and for licensing and acquisitions. Prior to joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company in a number of leadership roles, including sales management, marketing, human resources, sales and marketing, and oncology drug development. Mr. Nicholson earned a bachelor of science degree in pharmacy from the University of North Carolina, Chapel Hill, and a master of business administration degree from the University of South Carolina, Columbia.